1809010-52-3
Chemical Structure
Berotralstat dihydrochloride
Synonym(s): BCX7353 dihydrochloride
- CAS No.: 1809010-52-3
- Formula:C30H28Cl2F4N6O
- Molecular Weight:635.48
IUPAC Name: (R)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride
InChIKey: XFZLBLTUANGZBD-QDSLRZTOSA-N
SMILES: O=C(C1=CC(C(F)(F)F)=NN1C2=CC(CN)=CC=C2)NC3=CC([C@@H](C4=CC(C#N)=CC=C4)NCC5CC5)=CC=C3F.[H]Cl.[H]Cl
Biological Activity: Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Berotralstat dihydrochloride | 98.67% | Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Berotralstat dihydrochloride (Standard) | ≥98% | Berotralstat dihydrochloride (Standard) is the analytical standard of Berotralstat (dihydrochloride) (HY-109127A). This product is intended for research and analytical applications. Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.98
HY-109127Berotralstat -
Similarity Score 0.64
HY-11090ADPC423 -
Similarity Score 0.63
HY-11090DPC423 free base -
Similarity Score 0.54
HY-10758FXa-IN-1 -
Similarity Score 0.53
HY-11091Razaxaban hydrochloride -
Similarity Score 0.53
HY-10278Razaxaban -
Similarity Score 0.50
HY-146110RyRs activator 2 -
Similarity Score 0.47
HY-184536DCN1 modulator-1 -
Similarity Score 0.47
HY-146109RyRs activator 1 -
Explore the MedChemAI to find more analogs
References
- [1]. Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020;S0091-6749(20)31484-6. [Content Brief]
- [2]. Richard E. Kast, et al. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma. Neuroglia. 2024, 5(3), 223-233.
